Wednesday, October 2, 2013

Seeking Alpha: TearLab Builds Its Bench

The ups and downs of life as a small-cap med-tech company go on for TearLab (TEAR). There's still plenty of controversy regarding this name, not the least of which is a mixed bag of clinical papers on the company's osmolarity system, but strong system bookings certainly haven't done the stock any harm.

Most recently, though, the company announced the appointment of Seph Jensen, a long-time Alcon (part of Novartis (NVS)) veteran, as the company's new President and COO. Not only can Jensen bring experience on the device side of ophthalmology to the company and help the company appropriately build its sales/marketing efforts, but the addition of an industry veteran from a well-known company helps the image of TearLab as well.

Please follow this link to continue:
TearLab Builds Its Bench

No comments: